Mesenbio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $1.78M

  • Investors
  • 5

Mesenbio General Information

Description

Developer of exosome-based therapeutics designed to treat inflammatory and degenerative diseases. The company offers engineered extracellular vesicles with targeted delivery and scalable manufacturing, focusing on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translating the body of work into cutting-edge therapeutics, enabling pharmaceutical companies and healthcare providers to access advanced therapies for patients in immunology and regenerative medicine.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • University of York Wentworth Way
  • Department of Biology
  • York YO10 5DD
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • University of York Wentworth Way
  • Department of Biology
  • York YO10 5DD
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mesenbio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 09-Jan-2024 $1.78M Completed Generating Revenue
3. Accelerator/Incubator 11-Oct-2022 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. University Spin-Out 06-Dec-2021 Completed Generating Revenue
To view Mesenbio’s complete valuation and funding history, request access »

Mesenbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mesenbio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
DSW Ventures Venture Capital Minority
NG Bio (UK) Venture Capital Minority
SETsquared Partnership Accelerator/Incubator
University of York University
ICURe Accelerator/Incubator
To view Mesenbio’s complete investors history, request access »

Mesenbio FAQs

  • When was Mesenbio founded?

    Mesenbio was founded in 2021.

  • Where is Mesenbio headquartered?

    Mesenbio is headquartered in York, United Kingdom.

  • What is the size of Mesenbio?

    Mesenbio has 6 total employees.

  • What industry is Mesenbio in?

    Mesenbio’s primary industry is Drug Discovery.

  • Is Mesenbio a private or public company?

    Mesenbio is a Private company.

  • What is Mesenbio’s current revenue?

    The current revenue for Mesenbio is .

  • How much funding has Mesenbio raised over time?

    Mesenbio has raised $1.78M.

  • Who are Mesenbio’s investors?

    DSW Ventures, NG Bio (UK), SETsquared Partnership, University of York, and ICURe have invested in Mesenbio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process